Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Hetero ring is six-membered consisting of one nitrogen and five carbon atoms

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514183000 - Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514279000 Polycyclo ring system having the six-membered hetero ring as one of the cyclos 2794
514315000 Piperidines 999
514336000 Additional hetero ring containing 965
514278000 Spiro ring system 264
514345000 Chalcogen bonded directly to ring carbon of the six-membered hetero ring 225
514354000 C=O bonded directly to the six-membered hetero ring 182
514332000 Plural six-membered hetero rings consisting of one nitrogen and five carbon atoms 182
514357000 Nitrogen attached indirectly to the six-membered hetero ring by nonionic bonding 139
514352000 Nitrogen attached directly to the six-membered hetero ring by nonionic bonding 101
514358000 The ring nitrogen of the six-membered hetero ring is pentavalent (e.g., quaternary pyridinium salt, etc.) 16
514344000 Cyano bonded directly to the six-membered hetero ring 6
Entries
DocumentTitleDate
20130210849Methods for treating disorders associated with mGLU receptors including addiction and depression - Methods are provided for treating disorders associated with mGlu receptors by simultaneously inhibiting at least two mGluRs belonging to at least two different groups. In one embodiment, there are provided methods for treating a disorder associated with mGlu receptors 2, 3, and 5, including administering to a subject in need thereof an effective amount of at least one antagonist which modulates mGluR2, mGluR3, and mGluR5. The disorders treated by the method include, for example, nicotine addiction, cocaine addiction, and depression.08-15-2013
20090105288CARBON LINKED MODULATORS OF gamma-SECRETASE - The present invention relates to compounds of Formula I as shown below, wherein the definitions of A, X, R04-23-2009
20100087468MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION - The present invention is directed to certain novel compounds represented by Formula (I) and pharmaceutically acceptable salts, solvates, hydrates and prodrugs thereof. The present invention is also directed to methods of making and using such compounds and pharmaceutical compositions containing such compounds to treat or control a number of diseases mediated by PPAR such as glucose metabolism, lipid metabolism and insulin secretion, specifically Type 2 diabetes, hyperinsulinemia, hyperlipidemia, hyperuricemia, hypercholesteremia, atherosclerosis, one or more risk factors for cardiovascular disease, Syndrome X, hypertriglyceridemia, hyperglycemia, obesity and eating disorders.04-08-2010
20080293752Antiseptic body glide - An antiseptic body glide is a body glide with antiseptic properties. The antiseptic components do not interfere with other body glide components such as lubricants or preservatives. Additionally, the antiseptic body glide does not react unfavorably with latex. The antiseptic components do not have a bad taste or react with the other components to produce a bad taste. As such, the antiseptic body glide enhances intimate activities without compromising those activities in any way.11-27-2008
20100022570NOVEL MICROBIOCIDES - Compounds of the formula (I) in which the substituents are as defined in claim 01-28-2010
20100137347SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS - Disclosed herein is a compound of the formula (I). Therapeutic methods, compositions, and medicaments, related thereto are also disclosed.06-03-2010
20120088784Substituted Aromatic Compounds and Pharmaceutical Uses thereof - The present invention relates to substituted aromatic compounds of Formula I and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds in the prevention and/or treatment of various diseases and conditions in subjects, including the prevention or treatment of (i) blood disorders, (ii) renal disorders, a nephropathies, or renal disorder complications; (iii) inflammatory-related diseases; and/or (iv) oxidative stress related disorders.04-12-2012
20090069361METHODS OF TREATMENT USING (+)- ISOPROPYL 2-METHOXYETHYL 4-(2-CHLORO-3-CYANO-PHENYL)-1, 4-DIHYDRO-2, 6-DIMETHYL-PYRIDINE-3, 5-DICARBOXYLATE - The present invention relates to methods of treatment using the compound (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate, as a sole active agent or in combination with other pharmacological agents.03-12-2009
20090312354DHA Esters and Use Thereof In Treatment and Prevention of Cardiovascular Disease - The present invention relates to a docosahexaenoic acid ester with an alcohol chosen among the group-B vitamins or provitamins, advantageously comprised by: nicotinyl alcohol of the following formula (I), panthenol of the following formula (II), and inositol of the following formula (III) or with isosorbide of the following formula (IV) or isosorbide mononitrate of the following formula (V). It also relates to a method of preparation of same, a pharmaceutical composition comprising same and the use of same in the treatment or prevention of cardiovascular disease, in particular auricular fibrillation.12-17-2009
20100035908SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS - The present invention relates to a compound according to formula: (I); wherein X02-11-2010
20100249166DIFFERENTIAL EVAPORATION POTENTIATED DISINFECTANT SYSTEM - Antimicrobial compositions and methods of using such antimicrobial compositions to provide a reduction in populations of viable microorganisms.09-30-2010
20100249165PDZ DOMAIN MODULATORS - This invention relates to compounds useful as PDZ domain modulators, in particular the PDZ domain of PICK1.09-30-2010
20090163526Process for the Preparation of an Anti Microbial Extract from Leaves of the Plant Callistemon Rigidus - A process for the preparation of an antimicrobial extract from leaves of the plant 06-25-2009
20110172258INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS - Compounds of formula (Ia):07-14-2011
20090264453GENETIC POLYMORPHISMS ASSOCIATED WITH CORONARY HEART DISEASE, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with coronary heart disease, and in particular MI, and response to drug treatment. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.10-22-2009
20100137346DESFERRITHIOCIN ANALOGUE ACTINIDE DECORPORATION AGENTS - A pharmaceutical composition comprising a non-toxic effective amount of an actinide decorporation agent and a pharmaceutically acceptable carrier therefore, the actinide decorporation agent comprising a hexacoordinate desferrithiocin analogue capable of chelating an actinide in vivo and a method for removing an actinide from the tissue of a human or nonhuman mammal.06-03-2010
20090062321Hydroxybenzoate Salts Of Metanicotine Compounds - Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form.03-05-2009
20110269786TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME IN DIABETIC PATIENTS USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES - Administration of sPLA11-03-2011
20080262011Modulator - The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt thereof. Formula (I), wherein R10-23-2008
20090239888Methods for Inhibiting Amyloid Precursor Protein and Beta-Amyloid Production and Accumulation - Compositions and uses of mGluR09-24-2009
20090258889PESTICIDAL COMPOSITIONS - The present disclosure relates to pesticidal compositions and to methods for controlling pests such as insects and other arthropods. More particularly, the disclosure relates to a pesticidal compositions containing mineral oil and one or more additional components which, when used in combination, act synergistically to control insect and pest populations.10-15-2009
20100152220INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS - Compounds of formula (Ia):06-17-2010
20090076048DEUTERIUM-ENRICHED XALIPRODEN - The present application describes deuterium-enriched xaliproden, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-19-2009
20100197713BUTONE DERIVATIVES USEFUL AS COOLING AGENTS - Cooling compounds of formula (I) wherein R08-05-2010
20090170886ANDROGEN MODULATORS - The present invention is directed to a new class of benzonitriles and to their use as androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease excess sebum secretions and to stimulate hair growth.07-02-2009
20110009439INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS - Compounds of formula (Ia):01-13-2011
20110082166NOVEL 4-BENZHYDRYL-TETRAHYDRO-PYRIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - This invention relates to novel 4-benzhydryl-tetrahydro-pyridine derivatives of Formula (I), any of its stereoisomers or any mixture of its stereoisomers, or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, wherein R04-07-2011
20090312355Non-Flushing Niacin Analogues, and Methods of Use Thereof - One aspect of the present invention relates to substituted pyridines and pharmaceutically acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. The present invention also relates to methods of treating a range of mammalian maladies or conditions, including but not limited to hyperlipidemia, hypercholesterolemia, atherosclerosis, coronary artery disease, congestive heart failure, cardiovascular disease, hypertension, coronary heart disease, angina, pellagra, Hartnup's syndrome, carcinoid syndrome, arterial occlusive disease, obesity, hypothyroidism, vasoconstriction, osteoarthritis, rheumatoid arthritis, diabetes, Alzheimer's disease, lipodystrophy, or dyslipidemia, raising serum high-density lipoprotein (HDL) levels, and lowering serum low-density lipoprotein (LDL) levels.12-17-2009
20110105545GPBP inhibition using Q2 peptidomimetics - Disclosed are compounds of formula:05-05-2011
20090118317Statin-Carboxyalkylether Combinations - The invention is a pharmaceutical composition comprising a carboxyalkylether which lowers triglycerides and elevated HDL, and a statin which inhibits HMG-CoA reductase, thereby reducing LDL, said composition being useful for treating vascular diseases.05-07-2009
20110028504Formulation of radioprotective alpha beta unsaturated aryl sulfones - A pharmaceutical composition is provided for administration prior to or after exposure to ionizing radiation for reducing toxic effects of the radiation in a subject. An effective amount of the pharmaceutical composition provided comprising an effective amount of at least one radioprotective α, β unsaturated aryl sulfone, and at least one component selected from the group consisting of a) at least one water soluble polymer in an amount between about 0.5% and about 90% w/v, b) at least one chemically modified cyclodextrin in an amount between about 20% and about 60% w/v, and c) DMA in an amount between about 10% and about 50% w/v.02-03-2011
20090176814COMBINATIONS OF POTASSIUM CHANNEL OPENERS AND SODIUM CHANNEL INHIBITORS OR SODIUM CHANNEL-INFLUENCING ACTIVE COMPOUNDS FOR TREATING PAINS - The invention relates to pharmaceutical combinations of potassium channel openers and sodium channel inhibitors. for treating pains which are accompanied by an increase in muscle tone.07-09-2009
20100016347SERIES OF SKIN WHITENING (LIGHTENING) COMPOUNDS - The present invention is directed to inhibitors of tyrosinase, pharmaceutical compositions comprising such tyrosinase inhibitors, and methods of making and using the same. Specifically, included in the present invention are compositions of matter comprised of at least one 2,4-dihydroxybenzene analog, which inhibit the activity of tyrosinase and which inhibit the overproduction of melanin.01-21-2010
20100016346ELASMOBRANCH-REPELLING DOMPOUNDS AND METHODS OF USE - Compounds for repelling elasmobranch having an aldehyde or derivative, a carboxylic acid a derivative, a ketone or a derivative thereof, a di-ketone or a derivative thereof, a pyridine or derivative thereof, or an antipyrine or a derivative thereof and methods of use thereof.01-21-2010
20090275601Novel Pyriproxyfen Compositions - New pesticidal compositions comprising pyriproxyfen and methyl esters of C11-05-2009
20100197712USE OF DOPAMINE STABILIZERS - At least one embodiment of the present invention relates to the use of a dopamine stabilizing substance in an oral, subcutaneous or intramuscular daily dose of 1-20 mg or in an intravenous daily dose of 0.1-2 mg in treatment of a neurological or psychiatric disorder characterized by a hypofunction of the dopamine system. At least one embodiment of the invention also relates to the use of a dopamine stabilizing substance in an oral, subcutaneous or intramuscular daily dose of 25-50 mg in treatment of a disorder caused by instability of neural circuits.08-05-2010
20110105544CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER - The invention provides novel compounds of formula (I), wherein: R05-05-2011
20120122908Novel C-4 Substituted Retinoids - C-4 substituted retinoic acid analogs, synthesis methods of C-4 substituted retinoic acid analogs and methods of using C-4 substituted retinoic acid analogs to treat various cancers and dermatological diseases and conditions. The C-4 substituted retinoic acid analogs include C-4 all-trans retinoic acid (ATRA) and 13-cis retinoic acid (13-CRA) analogs. The C-4 substituted retinoic acid analogs inhibit all-trans retinoic acid (ATRA) 4-hydroxylase activity, thereby inhibiting the catabolism of ATRA. The C-4 substituted retinoic acid analogs also have ATRA-mimetic activity. The preferred substitutions at C-4 are an azole group, a sulfur, oxygen, or nitrogen containing group, a pyridyl group, an ethinyl group, a cyclopropyl-amine group, an ester group, or a cyano group, or forms, together with the C-4 carbon atom, an oxime, an oxirane or aziridine group.05-17-2012
20090318485NOVEL INHIBITORS OF RHO KINASE - The present invention relates to compounds and methods which may be useful as inhibitors of Rho kinase for the treatment or prevention of disease.12-24-2009
20100010027ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE - The present invention provides a method of treating glaucoma or ocular hypertension which comprises applying to the eye of a person in need thereof an amount sufficient to treat glaucoma or ocular hypertension of a compound of formula I01-14-2010
201002042561-PHENYL-2-PYRIDINYL ALKYL ALCOHOL COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS - 1-Phenyl-2-pyridinyl alkyl alcohol compounds are effective as inhibitors of the phosphodiesterase 4 (PDE4) enzyme and may be used to prevent and/or treat certain diseases or conditions.08-12-2010
20080255173Novel Specific Caspase-10 Inhibitors - The invention relates to compounds of the general formula (I), and to their use as caspase-10 inhibitors, especially for the treatment of diabetic retinopathy.10-16-2008
20080221141Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency - Spirocyclic cyclohexane compounds useful in pharmaceutical compositions for use in the treatment of substance dependency.09-11-2008
20110237613DHA ESTERS AND USE THEREOF IN TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE - The present invention relates to a docosahexaenoic acid ester with an alcohol chosen among the group-B vitamins or provitamins, advantageously comprised by: nicotinyl alcohol of the following formula (I), panthenol of the following formula (II), and inositol of the following formula (III) or with isosorbide of the following formula (IV) or isosorbide mononitrate of the following formula (V). It also relates to a method of preparation of same, a pharmaceutical composition comprising same and the use of same in the treatment or prevention of cardiovascular disease, in particular auricular fibrillation.09-29-2011
20100298367Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders - The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I or the general formula III:11-25-2010

Patent applications in class Hetero ring is six-membered consisting of one nitrogen and five carbon atoms

Patent applications in all subclasses Hetero ring is six-membered consisting of one nitrogen and five carbon atoms